Abstract Little is known of cancer rehabilitation needs in Europe. EUROCHIP-3 organised a group of experts to propose a list of population-based indicators used for describing cancer rehabilitation across Europe. The aim of this study is to present and discuss these indicators. A EUROCHIP-3 expert panel reached agreement on two types of indicators. (a) Cancer prevalence indicators. These were proposed as a means of characterising the burden of cancer rehabilitation needs by time from diagnosis and patient health status. These indicators can be estimated from cancer registry data or by collecting data on follow-up and treatments for samples of cases archived in cancer registries. (b) Indicators of rehabilitation success. These include: return to work, quality of life, and satisfaction of specific rehabilitation needs. Studies can be performed to estimate these indicators in individual countries, but to obtain comparable data across European countries it will be necessary to administer a questionnaire to randomly selected samples of patients from population-based cancer registry databases. However, three factors complicate questionnaire studies: patients may not be aware that they have cancer; incomplete participation in surveys could lead to bias; and national confidentiality laws in some cases prohibit cancer registries from approaching patients. Although these studies are expensive and difficult to perform, but as the number of cancer survivors increases, it is important to document their needs in order to provide information on cancer control.
Introduction
Cancer survival is increasing in Europe as a result of early diagnosis and improved treatment, 1 with the corollary that the proportion of persons in the population with a (past) diagnosis of cancer is growing. According to RARECARE estimates -based on cancer registry data -there were 3566 persons per 100,000 with a diagnosis of any type of cancer in the European Union on 1st January 2003, equivalent to a total prevalence of nearly 17.8 million. 2 The number of prevalent cancer cases is projected to increase as the European population continues to age, as cancer incidence increases, and as survival improves.
3 EUROCARE estimated that the proportion of patients (diagnosed from 1988 to 1999) considered cured of their cancer (all cancers combined) varied between 38% and 59% in women, and 21% and 47% in men, by country. 4 Cancer is often a chronic condition and patients may endure physical and psychological symptoms for years after their treatment is complete. 5 Such symptoms can worsen the quality of life, and include pain, fatigue, cognitive impairment, worries about health, irritable mood, demoralization, depression and interpersonal problems. 5 The Council of Europe has recognised that reducing the cancer burden in Europe will require an integrated approach to cancer control and has noted that 'to attain optimal results a patient-centred, comprehensive interdisciplinary approach and optimal psycho-social care should be implemented in routine cancer care, rehabilitation, post-treatment and follow-up'. 6 To provide data in the area of cancer rehabilitation needs, as part of its work-package 6 (WP-6) initiative, the European Cancer Health Indicator Project (EURO-CHIP-3) 7 recruited a group of unpaid experts to draw up a list of plausible population-based indicators able to describe cancer rehabilitation in Europe. The panel adopted the broad definition of rehabilitation proposed by the WHO: 'a process aimed at enabling patients to reach and maintain their optimal physical, sensory, intellectual, psychological and social functional levels'. 8 The panel also adopted a broad definition of cancer survivors: the total prevalence of persons in the population with a diagnosis of cancer. Before the first meeting, the WP-6 coordinator group prepared a list of possible rehabilitation indicators for consideration ( Table 1 , column 2). Between meetings, panel members carried out their own literature searches to find data on the indicators suggested. Also between meetings two ad hoc questionnaires were sent out to panel members soliciting further information and opinions (particularly from members not present at the previous meeting). The questionnaires, available online, 10 were devised by the WP-6 coordinator group typically in response to matters arising or decisions taken during previous meetings. The first questionnaire went out in April-June 2010 and solicited opinions on definitions, methods of determining and sources of data for estimating the indicators being considered. The second questionnaire, sent out in January-September 2011, solicited information for assessing the feasibility of using (estimating) the indicators being considered for adoption.
Criteria for selecting final list of indicators
It was agreed that any cancer rehabilitation indicator proposed must: (a) be available or estimable for entire populations; (b) describe the same aspect of cancer rehabilitation in all European countries and (c) be collectable by standardised methods in all countries.
Indicators were initially sought in the following domains: (i) cancer rehabilitation needs; (ii) prominence/presence of cancer rehabilitation on political and clinical agendas; (iii) cancer rehabilitation capabilities (structures, services and funding) and (iv) measures of rehabilitation success. Table 1 shows the indicators discussed and eventually adopted by the expert panel. The last column shows the final indicators proposed by the panel.
Systematic literature search
In order to find articles describing methods for estimating the indicators included in the final list, we carried out a systematic literature search in February 2012 using PubMed. 11 We first decided the search terms (first column, Table 2 ). We next examined abstracts of articles found, to identify those potential pertaining to indicators. Finally we read the Materials and Methods of articles apparently pertaining to indicators and selected those that were pertinent. Table 2 shows results of the PubMed search.
Results

Indicators on cancer rehabilitation needs
The expert panel found that the indicator best able to quantify patients with rehabilitation needs was total prevalence.
12 This indicator can be estimated from cancer registry data 12 or through mathematical modelling of mortality and survival data. 13 The EUROPREVAL 14 and RARECARE 2 projects produced estimates of total prevalence by cancer site in Europe in 1992 and 2003, respectively. Total prevalence comprises recentlydiagnosed patients, those undergoing treatment or follow-up and also long-term survivors, some of whom may be considered cured. It is useful to divide total prevalence into subgroups of cancer survivors having particular needs. One subdivision is according to time elapsed from diagnosis (e.g. two-year prevalence, five-year prevalence, which refers to survivors with diagnosis, respectively, in the two and five years preceding the prevalence index date). 13, 14 Years from diagnosis to reference date identifies (is a useful proxy for) groups of patients with differing healthcare needs. A study on prevalence by years from diagnosis was recently performed in the United Kingdom (UK). 15 GLOBOCAN 16 produced Europe-wide estimates of five-year prevalence for 2008. We found 40 other scientific articles dealing with population-based cancer prevalence in Europe (Table 2) .
It is also possible to apply cured models to cancer registry data to estimate the proportion of cured patients. This is the fraction of the total prevalence consisting of patients with the same life expectancy as the general population of the same age and sex; the remaining fraction consists of patients who will die of their disease and who may have different healthcare needs from cured patients. The proportion of cured patients indicator has been estimated by EUROCARE for all cancers combined and various cancer sites for several European countries. 4 It is also useful to identify other sub-groups of prevalent cases according to their clinical situation and likely demands on health care facilities. To do this, cancer registry data (incidence and vital status) are combined with information on treatment (or use of health service facilities) and follow-up (to identify recurrences, metastases, second tumours, side-effects of treatment, etc.) in order to produce estimates of what EUROCHIP-3 has designated differentiated prevalence, in which patients are divided according to their health status as follows: (a) cases not undergoing cancer treatment and without distant or local relapse; (b) cases expected to die of cancer within a year and probably requiring terminal care and home assistance (c) cases requiring health care or rehabilitation, expected to die of cancer after a year. 17 This has been shown to be feasible by studies performed in the UK on cancer survivors in general 18 and for colorectal cancer survivors in the US by linking hospital discharge data with cancer registry data. 19 Similar studies have also been performed in Italy [17] [18] [19] [20] 
Indicators on measures of rehabilitation success
The panel initially sought an indicator of return to work, since cancer survivors of working age are likely to be unemployed more often than healthy people. 22 Relatively few population-based studies have been performed on proportions of cancer survivors who return to work: the literature search found 12 articles (Table 2) . For example a Dutch study used the ArboNed Occupational Health Service register, containing sickness absence data and medical diagnoses for 1 million Dutch wage earners working in 33,000 companies in various economic sectors, to estimate return to work. [23] [24] [25] [26] Cancer registry data were linked to census data in Finland, 27, 28 with the Directorate of Taxes database in Norway, 29 and with the Labour Market Research Database in Denmark. 30, 31 However, these methods of study cannot be extended to other countries because the occupational databases exploited by these studies do not exist in most other European countries.
A feasible approach applicable to all European countries would be to perform surveys on samples of cancer survivors extracted from cancer registry databases. However, questionnaires would have to be compatible across languages and cultures. Surveys of this type have been performed in North West England (50% participation), 32 Ireland (54% participation) 33 and South Netherlands (80% participation). 34 The panel extensively examined the feasibility in collecting population-based data on quality of life of cancer patients, as this was considered an important indicator of cancer rehabilitation success. Table 3 summarises 41 European population-based studies on the quality of life, found by the literature search. These studies were mainly confined to the Netherlands, Germany, Sweden, Iceland and France; they can be considered populationbased as they involved samples of cases extracted from cancer registry databases, or were cross-sectional surveys of the general population linked to cancer registry databases. Various types of questionnaires were used; those used most frequently were EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer QLQ-C30), 35 SF-36 (36-item short form health survey), 36 and HADS (Hospital Anxiety and Depression Scale). 37 Participation varied from 32% to 94% with an average participation rate equal to 72%.
The panel also drew up a list of proxy indicators of rehabilitation needs and whether those needs are being met. These were: speech & language therapy for head and neck cancer patients; physiotherapy for breast cancer patients; dietary advice for colorectal cancer patients; and psychological support for all cancer patients. Our literature search on these indicators found two interesting articles. In one, data from a Swedish population-based prostate cancer registry was linked with the National Hospital Discharge Register and the National Prescribed Drug Register to find prostate cancer patients who had been hospitalised for psychiatric reasons or who used antidepressant drugs. 38 In the other, a survey (participation rate 54%) was carried out on cancer cases extracted from the Norwegian Cancer Registry to identify the proportions using specific rehabilitation services (physical therapy, physical training, psychological counselling, supportive group sessions, admittance to convalescent home, consultation with social worker and occupational therapy) to satisfy specific needs. 39 
Indicators excluded from the final list
The final list excluded the following indicators originally considered by the panel: (a) list of proxy yes/no (present/absent) indicators to assess the extent to which cancer rehabilitation was present on political and clinical agendas. Such information was considered too unreliable and subject to change to warrant inclusion in our list. (b) Indicators on the presence of rehabilitation structures and services, because the sources of information that were found proved not to be comparable across countries. (c) Indicators on cancer rehabilitation funding. Here replies to the first questionnaire made it clear that data on funding would be difficult to obtain, and also that even if this were possible, it was unlikely that funding data would be comparable across European countries.
Discussion
All indicators of cancer rehabilitation discussed by EUROCHIP-3 had two prerequisites: they had to be population-based and had to be collectable by 20, 21 or hospital discharge databases. 17 (b) Measures of the success of rehabilitation in terms of (i) return to work for patients of working age; (ii) quality of life and (iii) satisfaction of rehabilitation requirements (specifically, the panel chose to investigate speech and language therapy for head and neck cancer survivors, physiotherapy for breast cancer survivors, dietary therapy for colorectal cancer and psychological support for all cancers).
The success of rehabilitation has been estimated by a number of national studies. [23] [24] [25] [26] [29] [30] [31] 38 To quantify the rehabilitation services used by cancer survivors, cancer registry databases can be linked with those of the structures providing rehabilitation services. For example, a Danish study combined cancer registry and population-based databases to assess hospitalisation for depression as a measure of the psychological burden experienced by cancer patients. 41 However, this method only investigates rehabilitation needs that are being met; it can say nothing about survivors not present in rehabilitation service databases. Furthermore, these types of studies cannot be performed across the whole of Europe because the necessary databases are not uniformly present in all countries.
One way forward would be to collect data on the cancer experiences of cancer survivors by getting representative samples of them to complete validated questionnaires in all countries.
Information can also be collected through national health surveys of the general population (although such surveys would need to ask specifically whether the respondent had ever been diagnosed with cancer). Surveys can also be performed that are directed specifically at cancer survivors. Whatever method is used to obtain a picture of rehabilitation needs and facilities across Europe, the surveys must be conducted on population-based samples of survivors (i.e. sampled from cancer registry databases). Samples obtained from hospital databases are not representative of the population as a whole, and are therefore likely to provide biased and inaccurate information.
The Dutch experience with PROFILES (PatientReported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship) is relevant here. 42 All cancer patients archived in the Eindhoven cancer registry were asked to complete questionnaires whose objective was to investigate the physical and psychosocial impact of the cancer, and the involvement of patients' physicians in improving survivorship. 42 Other aspects need to be considered when organising and conducting surveys: (a) in some countries the survivor may not always be aware that he/she was diagnosed with cancer so in those situations the survivor's general practitioner or clinician must be contacted first; (b) national confidentiality laws may prevent cancer registries from contacting cancer patients; (c) if nonparticipation levels are high, the survey could provide false (biased) results. The PROFILES studies had 75-80% participation rates, 42 while other important studies in Norway, 39 the UK 32 and Ireland 33 had lower participation rates (50-55%). Getting patient organisations involved might improve participation rates. Although surveys are expensive and have the above-discussed limits, they have the potential to provide important information on cancer rehabilitation.
To conclude, as far as we are able to ascertain no other studies have investigated possible indicators of cancer rehabilitation in Europe. We are aware of the preliminary nature of our proposals, and intend the present the study as a starting point on which we hope other groups will build on and improve. We believe, particularly in view of the dramatic increase in numbers of cancer survivors in Europe (estimated to be 18 million in 2003), that it is important to start collecting information about cancer survivors as soon as possible through pilot studies, to identify their needs and whether they are being met, to obtain information on the availability of rehabilitation services in order to guide European cancer control policies in line with Council of Europe recommendations.
